UBS Group
IMVT icon

UBS Group’s Immunovant IMVT Stock Holding History

UBS Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,000
Closed -$384K – 10586
2025
Q2 		$384K Hold
24,000
– – ﹤0.01% 6234
2025
Q1 		$410K Hold
24,000
– – ﹤0.01% 6008
2024
Q4 		$594K Hold
24,000
– – ﹤0.01% 5718
2024
Q3 		$684K Hold
24,000
– – ﹤0.01% 4974
2024
Q2 		$634K Buy
+24,000
New +$683K ﹤0.01% 4808

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

UBS Group's IMVT Position: Q1 2026 in Review

UBS Group reduced its Immunovant (IMVT) stake by 6.5% in Q1 2026, selling an estimated $1.24M and leaving 684,551 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2780.

UBS Group first reported a position in IMVT in Q4 2019 and has held it in 25 quarters since. The position peaked at $18.6M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • UBS Group held 684,551 shares of Immunovant worth $17M as of Q1 2026.
  • UBS Group sold 47,835 Immunovant shares in Q1 2026, an estimated $1.24M.
  • Immunovant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2780 holding.
  • UBS Group first reported a position in Immunovant in Q4 2019 and has held it in 25 quarters since.
  • UBS Group's Immunovant position peaked at $18.6M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.